CIDP patient on treadmill

About Hizentra

Personalized Dosing & Administration

CIDP therapy
That fits your life

Convenient dosing lets you plan treatment around your life, instead of planning your life around treatment.

Prefilled Syringes

How do I infuse?

Explore the ways Hizentra Prefilled Syringes can simplify infusion setup vs. vials, saving time and effort

Watch the video or visit the self-administration page for a full instructional video

Full instructions

Be sure to get proper training from your healthcare provider before self-infusing Hizentra.

Melaine, a patient advocate preparing to self-infuse in her home

Flexible dosing

Adjustable dosing
to meet your needs

Hizentra offers adjustable dosing, so be sure to frequently update your doctor about how you're feeling so your doctor can personalize your treatment and identify the dose that works best for you.

EAN/PNS* medical guideline recommends adjusting subcutaneous immunoglobulin (SCIg) dose according to individual treatment response

*The European Academy of Neurology (EAN) and Peripheral Nerve Society (PNS) are two independent, international organizations of scientists, physicians, and other healthcare providers working together to investigate and treat neurological conditions and promote excellence leading to better care and outcomes.

Infusions with Hizentra usually take about
1 hour per week

Infusion time may be shorter or longer depending on the dose and frequency your doctor has prescribed for you.

You and your neurologist can create your Hizentra dosing schedule based on:

  • Your routine
  • How long infusions take
  • How much medicine per infusion
  • How many infusion sites

Not just simple.
Hizentra PFS simple.

Hizentra Prefilled Syringes (PFS) give you proven protection with a first and only for Ig

Simple, convenient, and ready to use

  • Simplifies infusion preparation vs. vials
  • Wide range of sizes for your individual needs
  • Select sizes are directly compatible with common infusion pumps
    • All sizes can be transferred to a pump compatible syringe using a syringe-to-syringe transfer device
Prefilled syringes and available in 1g, 2g,, 4g, and 10g doses
A man reclining on a couch feeling content

Insights from a CSL-sponsored Harris Poll survey

Satisfaction with prefilled syringes was high

In a CSL-sponsored Harris Poll survey, at least 91% were very/somewhat satisfied with:

  • Ability to personalize treatment
  • Overall convenience
  • Overall ease of administration
  • Ability to fit treatment into their lifestyle

In an online survey, at least 48 of 53 people with CIDP who self-infused Ig in prefilled syringes were very/somewhat satisfied on all measures mentioned.

Real patient stories

See how Ig infusions can be simpler
and more convenient

Watch Arthur experience the freedom and simplicity of using Hizentra Prefilled Syringes for CIDP maintenance.

Arthur, a patient advocate, living with CIDP,  with infusion kit

Patient profiles

Choose a patient to see how Hizentra self-infusions
help answer their CIDP treatment burdens

Clinical Challenges

Richard is a business manager with a wife and two sons. The ups and downs associated with IVIg infusions brought physical challenges, affecting his ability to work and spend time with his family. Switching to Hizentra provided consistent Ig levels, which helped him maintain his energy and strength.

  • Dose: 33 g/165 mL
  • Rate of infusion: 50 mL/hr/site
  • Infusion sites: 4
  • Time per infusion: ~50 minutes*

Based on a dose of 0.4 g/kg.

Calendar graphic

James is a software developer with a wife and teenage daughter. After hearing about the multiple systemic side effects (like headache and nausea) James experienced after every IVIg infusion and how they affected his work and family life, his doctor decided to put James on Hizentra. He finds time every weekend to relax at home and infuse his Hizentra.

  • Dose: 19 g/95 mL
  • Rate of infusion: 40 mL/hr/site
  • Infusion sites: 2
  • Time per infusion: ~1 hour and 10 minutes*

Based on a dose of 0.2 g/kg.

Calendar graphic

Alice is a retired engineer who leads a quiet and relaxed life. She was tired of nurses not finding her veins and didn't want a port put in, so she talked to her doctor and started Hizentra. She now infuses at home once a week with the assistance of her caregiver.

  • Dose: 15 g/75 mL
  • Rate of infusion: 30 mL/hr/site
  • Infusion sites: 2
  • Time per infusion: ~1 hour and 15 minutes*

Based on a weekly dose of 0.2 g/kg.

Calendar graphic

Lifestyle Burdens

Miguel is an artist and part-time teacher who required frequent IV infusions to manage his disease. His frequent trips to the IV clinic were also a hassle. So he asked his doctor about Hizentra. They decided self-infusing at home on his own schedule was right for him. More frequent infusions mean less volume per infusion, letting him infuse in just about an hour. After discussing with his doctor, Miguel prefers prefilled syringes because he has difficulty drawing from vials.

  • Dose: 32 g/160 mL (2 sessions over 2 days)
  • Rate of infusion: 40 mL/hr/site
  • Infusion sites: 2
  • Time per infusion: ~1 hour*

Based on a weekly dose of 0.4 g/kg

Calendar graphic

Allison is a working mother with 3 young children. After talking with her doctor, she chose Hizentra so she could fit her infusions around her busy work and home schedule. Allison asked her doctor about appropriate places to infuse, and now she can decide where and when she self-infuses with ready-to-use prefilled syringes. She needs a dosing schedule that won't get in the way of work and taking care of her kids.

  • Dose: 28 g/140 mL
  • Rate of infusion: 45 mL/hr/site
  • Infusion sites: 3
  • Time per infusion: ~1 hour*

Based on a weekly dose of 0.4 g/kg.

Calendar graphic

*Infusion times may vary and are dependent on the pump brand and type of syringe used.

Hypothetical case studies use recommended dose and labeled initial rate and volume per site, as well as maximum number of infusion sites. Photos do not depict actual patients.

Learn more about getting started with Hizentra

Important Safety Information

WARNING: Thrombosis (blood clots) can occur with immune globulin products, including Hizentra. Risk factors can include: advanced age, prolonged immobilization, a history of blood clotting or hyperviscosity (blood thickness), use of estrogens, installed vascular catheters, and cardiovascular risk factors.

If you are at high risk of blood clots, your doctor will prescribe Hizentra at the minimum dose and infusion rate practicable and will monitor for signs of clotting events and hyperviscosity. Always drink sufficient fluids before infusing Hizentra.

See your doctor for a full explanation, and the full prescribing information for complete boxed warning.

Hizentra®, Immune Globulin Subcutaneous (Human), 20% Liquid, is a prescription medicine used to treat:

  • Primary immune deficiency (PI) in patients 2 years and older
  • Chronic inflammatory demyelinating polyneuropathy (CIDP) in adults

Treatment with Hizentra might not be possible if your doctor determines you have hyperprolinemia (too much proline in the blood), or are IgA-deficient with antibodies to IgA and a history of hypersensitivity. Tell your doctor if you have previously had a severe allergic reaction (including anaphylaxis) to the administration of human immune globulin. Tell your doctor right away or go to the emergency room if you have hives, trouble breathing, wheezing, dizziness, or fainting. These could be signs of a bad allergic reaction.

Inform your doctor of any medications you are taking, as well as any medical conditions you may have had, especially if you have a history of diseases related to the heart or blood vessels, or have been immobile for some time. Inform your physician if you are pregnant or nursing, or plan to become pregnant.

Infuse Hizentra under your skin only; do not inject into a blood vessel.

Self-administer Hizentra only after having been taught to do so by your doctor or other healthcare professional, and having received dosing instructions for treating your condition.

Immediately report to your physician any of the following symptoms, which could be signs of serious adverse reactions to Hizentra:

  • Reduced urination, sudden weight gain, or swelling in your legs (possible signs of a kidney problem).
  • Pain and/or swelling or discoloration of an arm or leg, unexplained shortness of breath, chest pain or discomfort that worsens on deep breathing, unexplained rapid pulse, or numbness/weakness on one side of the body (possible signs of a blood clot).
  • Bad headache with nausea; vomiting; stiff neck; fever; and sensitivity to light (possible signs of meningitis).
  • Brown or red urine; rapid heart rate; yellowing of the skin or eyes; chest pains or breathing trouble; fever over 100°F (possible symptoms of other conditions that require prompt treatment).

Hizentra is made from human blood. The risk of transmission of infectious agents, including viruses and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent and its variant (vCJD), cannot be completely eliminated.

The most common side effects in the clinical trials for Hizentra include redness, swelling, itching, and/or bruising at the infusion site; headache; chest, joint or back pain; diarrhea; tiredness; cough; rash; itching; fever, nausea, and vomiting. These are not the only side effects possible. Tell your doctor about any side effect that bothers you or does not go away.

Before receiving any vaccine, tell immunizing physician if you have had recent therapy with Hizentra, as effectiveness of the vaccine could be compromised.

Please see full prescribing information for Hizentra, including boxed warning and the patient product information.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

You can also report side effects to CSL Behring's Pharmacovigilance Department at 1-866-915-6958.

View information about Hizentra for:
You are leaving the current website.

The site you are accessing is maintained by a third party over whom CSL Behring has no control. CSL Behring does not review, approve, or necessarily endorse viewpoints, inferences, or conclusions stated in or implied by the content of this site. CSL Behring is not responsible for third-party content or the consequences of your use thereof.

Do you want to continue?